PARIS, April 20 An estimated 2,150 to 4,100
children in France suffered a major malformation in the womb
between 1967 and 2016 after their mothers took a treatment
against epilepsy and bipolar disorders known as valproate,
France's drug regulator said on Thursday.
Valproate, which has been manufactured in France by Sanofi
under the brand Depakine in the field of epilepsy and
Depakote and Depamide in bipolar disorders, is also believed to
cause slow neurological development.
ANSM, France's drug authority, said it would also publish a
study on neurological effects in the second half of 2017.
Sanofi was not immediately available for comment.
Valproate was approved as an anti-epileptic drug in France
in 1967 and has become one of the most widely prescribed
treatments for the condition worldwide.
Parents of those affected say the French state and Sanofi
were too slow to warn of the side effects of the drug, after the
risks to foetuses became clear by the early 1980s.
(Reporting by Matthias Blamont, Editing by Sarah White)